Evidence map›Paper›PMID 37217763›Full record

ArticleBreast cancer (Tokyo, Japan)2023

Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR + , HER2- metastatic breast cancer patients in Japan.

K Nozawa, M Terada, M Onishi, Y Ozaki, T Takano, W Fakhouri, D Novick, J M Haro, L H Faris, T Kawaguchi and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer (Tokyo, Japan), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Observational
  5. Review
  6. Article
  7. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 3 countries.

K NozawaDepartment of Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
M TeradaDepartment of Breast Surgery, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
M OnishiDepartment of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Y OzakiDepartment of Breast Medical Oncology, Breast Oncology Center, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
T TakanoDepartment of Breast Medical Oncology, Breast Oncology Center, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
W FakhouriEli Lilly and Company, Indianapolis, IN, USA.
D NovickEli Lilly and Company, Indianapolis, IN, USA.
J M HaroParc Sanitari Sant Joan de Déu, Universitat de Barcelona, Sant Boi de Llobregat, Barcelona, Spain.
L H FarisParc Sanitari Sant Joan de Déu, Universitat de Barcelona, Sant Boi de Llobregat, Barcelona, Spain.
T KawaguchiEli Lilly and Company, Indianapolis, IN, USA.
Y TanizawaEli Lilly and Company, Indianapolis, IN, USA.
Junji TsurutaniAdvanced Cancer Translational Research Institute, Showa University, Tokyo, Japan. tsurutaj@med.showa-u.ac.jp.ORCID http://orcid.org/0000-0002-6260-6943
Eli Lilly (United States) · USParc Sanitari Sant Joan de Déu · ESThe Cancer Institute Hospital · JPAichi Cancer Center · JPNagoya City University · JPNational Cancer Center Hospital East · JPShowa University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis study described, in routine clinical practice in Japan, the patient characteristics, treatment patterns, and outcomes of female patients with HR + /HER2- metastatic breast cancer (MBC) who started abemaciclib treatment.

methodsClinical charts were reviewed for patients starting abemaciclib in 12/2018-08/2021 with a minimum of 3 months follow-up data post-abemaciclib initiation regardless of abemaciclib discontinuation. Patient characteristics, treatment patterns, and tumor response were descriptively summarized. Kaplan-Meier curves estimated progression-free survival (PFS).

results200 patients from 14 institutions were included. At abemaciclib initiation, median age was 59 years, and the Eastern Cooperative Oncology Group performance status score was 0/1/2 for 102/68/5 patients (58.3/38.9/2.9%), respectively. Most had an abemaciclib starting dose of 150 mg (92.5%). The percentage of patients receiving abemaciclib as 1st, 2nd, or 3rd line treatment was 31.5%, 25.8%, and 25.2%, respectively. The most frequent endocrine therapy drugs used with abemaciclib were fulvestrant (59%) and aromatase inhibitors (40%). Evaluation of tumor response was available for 171 patients, 30.4% of whom had complete/partial response. Median PFS was 13.0 months (95% CI 10.1-15.8 months).

conclusionsIn a routine clinical practice setting in Japan, patients with HR + , HER2- MBC appear to benefit from abemaciclib treatment in terms of treatment response and median PFS, with the results broadly reflecting the evidence demonstrated in clinical trials.

Indexed as

Breast NeoplasmsAminopyridinesAntineoplastic Combined Chemotherapy ProtocolsBenzimidazolesErb-b2 Receptor Tyrosine KinasesFemaleFulvestrantHumansJapanMiddle AgedabemaciclibAminopyridinesBenzimidazolesErb-b2 Receptor Tyrosine KinasesFulvestrantAdvanced breast cancerCyclin-dependent kinasEstrogen receptorHER2-negativeProgesteron receptor

Identifiers

PMID37217763
PMCPMC10284953
OpenAlexW4377289713

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.